|
|
| | Spesolimab Basic information |
| Product Name: | Spesolimab | | Synonyms: | Spesolimab;Spesolimab (DHJ72801);Research Grade Spesolimab(DHJ72801);Research Grade Spesolimab;BI 655130;Spesolimab (anti-IL-1RL2) | | CAS: | 2097104-58-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Spesolimab Structure]() |
| | Spesolimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Spesolimab Usage And Synthesis |
| Uses | Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways[1][2][3][4]. | | References | [1] Mrowietz U, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. DOI:10.1007/s13555-021-00504-0
[2] Geller S, et al. CCR4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders and its implications for diagnosis and treatment[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2019, 139(9): B25-B25.
[3] Jennifer Ahlberg, et al. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5). MAbs. 2019 Jul;11(5):956-964. DOI:10.1080/19420862.2019.1615345
[4] Rajkumar Ganesan, et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.MAbs. 2017 Oct;9(7):1143-1154. DOI:10.1080/19420862.2017.1353853 |
| | Spesolimab Preparation Products And Raw materials |
|